Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence.
paper
Cited
Public
Unavailable
- Authors
- Malaiyandi, Viba; Sellers, Edward M; Tyndale, Rachel F
- Year
- 2005
- Journal
- Clinical pharmacology and therapeutics
- PMID
- 15735609
- DOI
- 10.1016/j.clpt.2004.10.011
Nicotine is the primary addictive compound in tobacco smoke. In this review we summarize nicotine dependence and the genetics of smoking in brief before focusing on cytochrome P450 (CYP) 2A6. In humans nicotine is mainly inactivated to cotinine and CYP2A6 mediates approximately 90% of this conversion. Some, but not all, studies suggest that genetic variation in CYP2A6 may play a role in smoking. We review some of the recent findings on the influence of CYP2A6 genetic polymorphisms on nicotine kinetics, smoking behaviors, and how the gene appears to exert differential effects during various stages of smoking (eg, initiation, conversion to dependence, amount smoked during dependence, and quitting). These new findings will be put in the context of the discrepancies found in the literature. Implications of these recent findings on current and novel treatment approaches for smoking cessation and tobacco-related lung cancer will also be discussed.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Inhibition of CYP2A6-mediated nicotine metabolism: A potential strategy for smoking cessation therapy. | Olawale ME et al. | β | 2026 | β |
| The clinical usefulness of knowing <i>CHRNA5</i> polymorphism genotype: paving the way for personalized therapy. | Colombo F et al. | β | 2026 | β |
| A blind spot in fMRI research: Overlooked tobacco smoking-related confounds. | Koster M et al. | β | 2025 | β |
| Perspectives on Using Pharmacogenomics to Guide Tobacco Cessation: Survey Results From an American Indian Community. | Wichman ML et al. | β | 2025 | β |
| The Role of Genetics in Stroke Risk and Outcome: A Review of Current Evidence. | Oyovwi MO et al. | β | 2025 | β |
| Efficacy of varenicline or bupropion and its association with nicotine metabolite ratio among smokers with COPD. | Qin R et al. | β | 2024 | β |
| Evidence for sex differences in the impact of cytochrome P450 genotypes on early subjective effects of cannabis. | Davis CN et al. | β | 2024 | β |
| Physiologic Effects of Substance Use. | Murray BP et al. | β | 2024 | β |
| Role of Cytochrome P450 3A4 in Cancer Drug Resistance: Challenges and Opportunities. | Pandey SK et al. | β | 2024 | β |
| Advice for smokers in smoking cessation clinic: a review. | Yu X et al. | β | 2023 | β |
| Biochemical and genetic biomarkers associated with nicotine dependence in Mexican smokers. | Borrego-Soto G et al. | β | 2023 | β |
| Multi-trait genome-wide association analyses leveraging alcohol use disorder findings identify novel loci for smoking behaviors in the Million Veteran Program. | Cheng Y et al. | β | 2023 | β |
| Associations of genetic risk, BMI trajectories, and the risk of non-small cell lung cancer: a population-based cohort study. | You D et al. | β | 2022 | β |
| Pharmacogenetic and drug interaction aspects on ketamine safety in its use as antidepressant - implications for precision dosing in a global perspective. | Langmia IM et al. | β | 2022 | β |
| How to manage cigarette smoking in kidney transplant candidates and recipients? | Devresse A et al. | β | 2021 | β |
| SNPs within CHRNA5-A3-B4 and CYP2A6/B6, nicotine metabolite concentrations and nicotine dependence treatment success in smokers. | Hubacek JA et al. | β | 2021 | β |
| Pharmacogenomics of Nicotine Metabolism: Novel CYP2A6 and CYP2B6 Genetic Variation Patterns in Alaska Native and American Indian Populations. | Claw KG et al. | β | 2020 | β |
| Considering Genetic Heterogeneity in the Association Analysis Finds Genes Associated With Nicotine Dependence. | Zhang X et al. | β | 2019 | β |
| Nicotine Metabolism in Adults With Type 2 Diabetes. | Keith RJ et al. | β | 2019 | β |
| Nicotine Pharmacokinetics in Rat Brain and Blood by Simultaneous Microdialysis, Stable-Isotope Labeling, and UHPLC-HRMS: Determination of Nicotine Metabolites. | Xu Y et al. | β | 2019 | β |
| Association of genetic polymorphisms CYP2A6*2 rs1801272 and CYP2A6*9 rs28399433 with tobacco-induced lung Cancer: case-control study in an Egyptian population. | Ezzeldin N et al. | β | 2018 | β |
| Brain substrates of early (4h) cigarette abstinence: Identification of treatment targets. | Franklin TR et al. | β | 2018 | β |
| Circadian Regulation of Hepatic Cytochrome P450 2a5 by Peroxisome Proliferator-Activated Receptor <i>Ξ³</i>. | Deng J et al. | β | 2018 | β |
| CYP2A6 metabolism in the development of smoking behaviors in young adults. | Olfson E et al. | β | 2018 | β |
| Nicotinic acetylcholine receptor gene polymorphism is not associated with tobacco-related oral squamous cell carcinoma. | Rajesh D et al. | β | 2018 | β |
| Preparing the Way: Exploiting Genomic Medicine to Stop Smoking. | Bierut LJ et al. | β | 2018 | β |
| Tobacco biomarkers and genetic/epigenetic analysis to investigate ethnic/racial differences in lung cancer risk among smokers. | Murphy SE et al. | β | 2018 | β |
| A Novel Tobacco Use Phenotype Suggests the 15q25 and 19q13 Loci May be Differentially Associated With Cigarettes per Day and Tobacco-Related Problems. | Richmond-Rakerd LS et al. | β | 2017 | β |
| Distribution of polymorphic variants of CYP2A6 and their involvement in nicotine addiction. | LΓ³pez-Flores LA et al. | β | 2017 | β |
| Effect of UGT2B10, UGT2B17, FMO3, and OCT2 genetic variation on nicotine and cotinine pharmacokinetics and smoking in African Americans. | Taghavi T et al. | β | 2017 | β |
| Genetic polymorphisms in CYP2A6 are associated with a risk of cigarette smoking and predispose to smoking at younger ages. | PΓ©rez-Rubio G et al. | β | 2017 | β |
| GRONS: a comprehensive genetic resource of nicotine and smoking. | Fang Z et al. | β | 2017 | β |
| Maternal Smoking during Pregnancy and Necrotizing Enterocolitis-associated Infant Mortality in Preterm Babies. | Ding G et al. | β | 2017 | β |
| Nicotine, Carcinogen, and Toxin Exposure in Long-Term E-Cigarette and Nicotine Replacement Therapy Users: A Cross-sectional Study. | Shahab L et al. | β | 2017 | β |
| Nicotine Metabolism and Smoking: Ethnic Differences in the Role of P450 2A6. | Murphy SE | β | 2017 | β |
| Predictors of Variation in CYP2A6 mRNA, Protein, and Enzyme Activity in a Human Liver Bank: Influence of Genetic and Nongenetic Factors. | Tanner JA et al. | β | 2017 | β |
| Prevalence and Impact of Long-term Use of Nicotine Replacement Therapy in UK Stop-Smoking Services: Findings From the ELONS Study. | Shahab L et al. | β | 2017 | β |
| Variation in CYP2A6 and nicotine metabolism among two American Indian tribal groups differing in smoking patterns and risk for tobacco-related cancer. | Tanner JA et al. | β | 2017 | β |
| CYP2A6 Effects on Subjective Reactions to Initial Smoking Attempt. | Cannon DS et al. | β | 2016 | β |
| CYP2A6 Longitudinal Effects in Young Smokers. | Cannon DS et al. | β | 2016 | β |
| Disposition kinetics and metabolism of nicotine and cotinine in African American smokers: impact of CYP2A6 genetic variation and enzymatic activity. | Benowitz NL et al. | β | 2016 | β |
| Racial differences in the relationship between rate of nicotine metabolism and nicotine intake from cigarette smoking. | Ross KC et al. | β | 2016 | β |
| Cytochrome P450 in Cancer Susceptibility and Treatment. | Mittal B et al. | β | 2015 | β |
| Does ethnic ancestry play a role in smoking? | De Souza ES et al. | β | 2015 | β |
| Evaluating Long-term Outcomes of NHS Stop Smoking Services (ELONS): a prospective cohort study. | Dobbie F et al. | β | 2015 | β |
| Pharmacogenetics of nicotine and associated smoking behaviors. | Tanner JA et al. | β | 2015 | β |
| Predictors of the nicotine reinforcement threshold, compensation, and elasticity of demand in a rodent model of nicotine reduction policy. | Grebenstein PE et al. | β | 2015 | β |
| Simultaneous determination of nicotine and its nine metabolites in rat blood utilizing microdialysis coupled with UPLC-tandem mass spectrometry for pharmacokinetic application. | Mao J et al. | β | 2015 | β |
| A comparison of nicotine biomarkers and smoking patterns in daily and nondaily smokers. | Shiffman S et al. | β | 2014 | β |
| Drug abuse and the neurovascular unit. | Egleton RD et al. | β | 2014 | β |
| Efficacy of S-1 in non-small cell lung cancer. | Kawahara M | β | 2014 | β |
| Finding genomic function for genetic associations in nicotine addiction research: the ENCODE project's role in future pharmacogenomic analysis. | Vandenbergh DJ et al. | β | 2014 | β |
| Nicotine gum or patch treatment for smoking cessation and smoking reduction: a multi-centre study in Chinese physicians. | Xiao D et al. | β | 2014 | β |
| Novel CYP2A6 variants identified in African Americans are associated with slow nicotine metabolism in vitro and in vivo. | Piliguian M et al. | β | 2014 | β |
| Pharmacokinetic and pharmacodynamics studies of nicotine after oral administration in mice: effects of methoxsalen, a CYP2A5/6 inhibitor. | Alsharari SD et al. | β | 2014 | β |
| Re-defininG AddiC(CH3)Tion: genomics and epigenomics on substance use disorders. | Rutter JL et al. | β | 2014 | β |
| Through the smoke: use of in vivo and in vitro cigarette smoking models to elucidate its effect on female fertility. | Camlin NJ et al. | β | 2014 | β |
| Variants in two adjacent genes, EGLN2 and CYP2A6, influence smoking behavior related to disease risk via different mechanisms. | Bloom AJ et al. | β | 2014 | β |
| Advances in genetic studies of substance abuse in China. | Sun Y et al. | β | 2013 | β |
| CYP2B6 non-coding variation associated with smoking cessation is also associated with differences in allelic expression, splicing, and nicotine metabolism independent of common amino-acid changes. | Bloom AJ et al. | β | 2013 | β |
| Cytochrome P450 2A isoenzymes in freshly prepared blood lymphocytes isolated from rats and validation as a biomarker for clinical studies in humans. | Sharma A et al. | β | 2013 | β |
| Cytochrome p450 part 2: what nurses need to know about the cytochrome p450 family systems. | Krau SD | β | 2013 | β |
| Effects upon in-vivo nicotine metabolism reveal functional variation in FMO3 associated with cigarette consumption. | Bloom AJ et al. | β | 2013 | β |
| Genetic and pharmacokinetic determinants of response to transdermal nicotine in white, black, and Asian nonsmokers. | Dempsey DA et al. | β | 2013 | β |
| Insula-specific H magnetic resonance spectroscopy reactions in heavy smokers under acute nicotine withdrawal and after oral nicotine substitution. | Gutzeit A et al. | β | 2013 | β |
| Nicotine metabolism and addiction among adolescent smokers. | Rubinstein ML et al. | β | 2013 | β |
| Polygenic risk and the developmental progression to heavy, persistent smoking and nicotine dependence: evidence from a 4-decade longitudinal study. | Belsky DW et al. | β | 2013 | β |
| Predictors of cessation in African American light smokers enrolled in a bupropion clinical trial. | Faseru B et al. | β | 2013 | β |
| Predictors of nicotine dependence symptoms among never-smoking adolescents: a longitudinal analysis from the Nicotine Dependence in Teens Study. | Racicot S et al. | β | 2013 | β |
| Race, gender, and nicotine metabolism in adolescent smokers. | Rubinstein ML et al. | β | 2013 | β |
| Age-associated changes in nicotine dependence. | Park S et al. | β | 2012 | β |
| CYP2A6 genetic variation and dexmedetomidine disposition. | Kohli U et al. | β | 2012 | β |
| Genetic polymorphisms of drug-metabolizing phase I enzymes CYP2E1, CYP2A6 and CYP3A5 in South Indian population. | Krishnakumar D et al. | β | 2012 | β |
| Metabolic capabilities of cytochrome P450 enzymes in Chinese liver microsomes compared with those in Caucasian liver microsomes. | Yang J et al. | β | 2012 | β |
| Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone binding and access channel in human cytochrome P450 2A6 and 2A13 enzymes. | DeVore NM et al. | β | 2012 | β |
| Nicotine vaccines to assist with smoking cessation: current status of research. | Raupach T et al. | β | 2012 | β |
| Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes. | Gold AB et al. | β | 2012 | β |
| PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6. | McDonagh EM et al. | β | 2012 | β |
| Smoking cessation for the neurologic patient. | Tavee J | β | 2012 | β |
| Use of a predictive model derived from in vivo endophenotype measurements to demonstrate associations with a complex locus, CYP2A6. | Bloom AJ et al. | β | 2012 | β |
| Absorption, distribution, metabolism and excretion pharmacogenomics of drugs of abuse. | Meyer MR et al. | β | 2011 | β |
| Alcohol use as a signal for sensitivity to nicotine dependence among recent onset smokers. | Dierker LC et al. | β | 2011 | β |
| An investigation of social and pharmacological exposure to secondhand tobacco smoke as possible predictors of perceived nicotine dependence, smoking susceptibility, and smoking expectancies among never-smoking youth. | Racicot S et al. | β | 2011 | β |
| Catalytic mechanism of cytochrome P450 for 5'-hydroxylation of nicotine: fundamental reaction pathways and stereoselectivity. | Li D et al. | β | 2011 | β |
| Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients. | Chuah B et al. | β | 2011 | β |
| Copy number polymorphisms and anticancer pharmacogenomics. | Gamazon ER et al. | β | 2011 | β |
| Design, baseline characteristics, and retention of African American light smokers into a randomized trial involving biological data. | Cox LS et al. | β | 2011 | β |
| Flexibility of human cytochrome P450 enzymes: molecular dynamics and spectroscopy reveal important function-related variations. | HendrychovΓ‘ T et al. | β | 2011 | β |
| Genetic polymorphisms in 15q25 and 19q13 loci, cotinine levels, and risk of lung cancer in EPIC. | Timofeeva MN et al. | β | 2011 | β |
| Maternal smoking during pregnancy, polymorphic CYP1A1 and GSTM1, and lung-function measures in urban family children. | Chen X et al. | β | 2011 | β |
| Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk. | Wassenaar CA et al. | β | 2011 | β |
| 'Smoking genes': a genetic association study. | Verde Z et al. | β | 2011 | β |
| The contribution of common CYP2A6 alleles to variation in nicotine metabolism among European-Americans. | Bloom J et al. | β | 2011 | β |
| Are adolescents with ADHD interested in genetic testing for nicotine addiction susceptibility? | Herbert LJ et al. | β | 2010 | β |
| Behavioral effects of nicotine withdrawal differ by genetic strain in male and female adolescent rats. | Hamilton KR et al. | β | 2010 | β |
| Common and unique biological pathways associated with smoking initiation/progression, nicotine dependence, and smoking cessation. | Wang J et al. | β | 2010 | β |
| Fundamental reaction pathways for cytochrome P450-catalyzed 5'-hydroxylation and N-demethylation of nicotine. | Li D et al. | β | 2010 | β |
| Glucuronidation genotypes and nicotine metabolic phenotypes: importance of functional UGT2B10 and UGT2B17 polymorphisms. | Chen G et al. | β | 2010 | β |
| Nicotine addiction. | Benowitz NL | β | 2010 | β |
| The Health Effect of Psychostimulants: A Literature Review. | Favrod-Coune T et al. | β | 2010 | β |
| 'To prove this is the industry's best hope': big tobacco's support of research on the genetics of nicotine addiction. | Gundle KR et al. | β | 2010 | β |
| UGT2B10 genotype influences nicotine glucuronidation, oxidation, and consumption. | Berg JZ et al. | β | 2010 | β |
| Abuse liability assessment of tobacco products including potential reduced exposure products. | Carter LP et al. | β | 2009 | β |
| Assessment of smoking status based on cotinine levels in nasal lavage fluid. | Ozdener MH et al. | β | 2009 | β |
| A systems biology network model for genetic association studies of nicotine addiction and treatment. | Thomas PD et al. | β | 2009 | β |
| beta2-Nicotinic acetylcholine receptor availability during acute and prolonged abstinence from tobacco smoking. | Cosgrove KP et al. | β | 2009 | β |
| Choice of environmental components for a longitudinal birth cohort study. | Golding J et al. | β | 2009 | β |
| Gene-gene interactions of CYP2A6 and MAOA polymorphisms on smoking behavior in Chinese male population. | Tang X et al. | β | 2009 | β |
| Genome-wide and candidate gene association study of cigarette smoking behaviors. | Caporaso N et al. | β | 2009 | β |
| Moderate use of alcohol, tobacco and cannabis during pregnancy: new approaches and update on research findings. | Huizink AC | β | 2009 | β |
| Molecular genetics of nicotine metabolism. | Mwenifumbo JC et al. | β | 2009 | β |
| Nicotine dependence: biology, behavior, and treatment. | Ray R et al. | β | 2009 | β |
| Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymes. | Ray R et al. | β | 2009 | β |
| Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. | Benowitz NL | β | 2009 | β |
| Polymorphisms in metabolic genes CYP1A1 and GSTM1 and changes in maternal smoking during pregnancy. | Chen X et al. | β | 2009 | β |
| Sex heterogeneity in pharmacogenetic smoking cessation clinical trials. | Schnoll RA et al. | β | 2009 | β |
| A novel CYP2A6 allele, CYP2A6*23, impairs enzyme function in vitro and in vivo and decreases smoking in a population of Black-African descent. | Ho MK et al. | β | 2008 | β |
| Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction. | Benowitz NL | β | 2008 | β |
| Dexamethasone-mediated up-regulation of human CYP2A6 involves the glucocorticoid receptor and increased binding of hepatic nuclear factor 4 alpha to the proximal promoter. | Onica T et al. | β | 2008 | β |
| Dose-response associations between maternal smoking during pregnancy and subsequent childhood obesity: effect modification by maternal race/ethnicity in a low-income US cohort. | Sharma AJ et al. | β | 2008 | β |
| Flexibility of human cytochromes P450: molecular dynamics reveals differences between CYPs 3A4, 2C9, and 2A6, which correlate with their substrate preferences. | SkopalΓk J et al. | β | 2008 | β |
| Genes and cigarette smoking. | MunafΓ² MR et al. | β | 2008 | β |
| Growth hormone does not alter CYP2A6 activity in growth hormone-deficient children. | SinuΓ©s B et al. | β | 2008 | β |
| Identification of inhibitors of the nicotine metabolising CYP2A6 enzyme--an in silico approach. | Rahnasto M et al. | β | 2008 | β |
| Neuroimaging, genetics and the treatment of nicotine addiction. | Ray R et al. | β | 2008 | β |
| Nicotine metabolism and urinary elimination in mouse: in vitro and in vivo. | Raunio H et al. | β | 2008 | β |
| PhRMA white paper on ADME pharmacogenomics. | Williams JA et al. | β | 2008 | β |
| Rate of nicotine metabolism and withdrawal symptoms in adolescent light smokers. | Rubinstein ML et al. | β | 2008 | β |
| Reduced CYP2D6 activity is a negative risk factor for methamphetamine dependence. | Otani K et al. | β | 2008 | β |
| Stability of the nicotine metabolite ratio in ad libitum and reducing smokers. | Mooney ME et al. | β | 2008 | β |
| The role of psychiatric disorders in the relationship between cigarette smoking and DSM-IV nicotine dependence among young adults. | Dierker L et al. | β | 2008 | β |
| Analysis of [3',3'-d(2)]-nicotine and [3',3'-d(2)]-cotinine by capillary liquid chromatography-electrospray tandem mass spectrometry. | Murphy SE et al. | β | 2007 | β |
| Application of nicotine enantiomers, derivatives and analogues in therapy of neurodegenerative disorders. | Pogocki D et al. | β | 2007 | β |
| A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. | Tsai ST et al. | β | 2007 | β |
| CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial. | Lee AM et al. | β | 2007 | β |
| Developing the science base for reducing tobacco harm. | Hatsukami DK et al. | β | 2007 | β |
| Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). | Alberg AJ et al. | β | 2007 | β |
| Estimation of urinary cotinine cut-off points distinguishing non-smokers, passive and active smokers. | ZieliΕska-Danch W et al. | β | 2007 | β |
| Genetics and smoking behavior. | Schnoll RA et al. | β | 2007 | β |
| Genetics and smoking cessation improving outcomes in smokers at risk. | Lerman CE et al. | β | 2007 | β |
| Genetic variability in CYP2A6 and the pharmacokinetics of nicotine. | Mwenifumbo JC et al. | β | 2007 | β |
| Genetic variation in catechol-O-methyltransferase (COMT) and obesity in the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial. | Wang SS et al. | β | 2007 | β |
| Genetic variation that contributes to nicotine dependence. | Bierut LJ | β | 2007 | β |
| Glucuronidation of nicotine and cotinine by UGT2B10: loss of function by the UGT2B10 Codon 67 (Asp>Tyr) polymorphism. | Chen G et al. | β | 2007 | β |
| Guidelines on nicotine dose selection for in vivo research. | Matta SG et al. | β | 2007 | β |
| Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. | Ingelman-Sundberg M et al. | β | 2007 | β |
| Interaction between nicotine and MPTP/MPP+ in rat brain endothelial cells. | Liou HH et al. | β | 2007 | β |
| Molecular cloning and functional characterization of psoralen synthase, the first committed monooxygenase of furanocoumarin biosynthesis. | Larbat R et al. | β | 2007 | β |
| N-7-Alkyl-2'-Deoxyguanosine as surrogate biomarkers for N-nitrosamine exposure in human lung. | Ganesan N et al. | β | 2007 | β |
| Overview of the pharmacogenomics of cigarette smoking. | Ho MK et al. | β | 2007 | β |
| Pharmacogenetics and smoking cessation with nicotine replacement therapy. | Ray R et al. | β | 2007 | β |
| The role of CYP2A6 in the emergence of nicotine dependence in adolescents. | Audrain-McGovern J et al. | β | 2007 | β |
| What common structural features and variations of mammalian P450s are known to date? | Otyepka M et al. | β | 2007 | β |
| A decrease in the plasma DHEA to cortisol ratio during smoking abstinence may predict relapse: a preliminary study. | Rasmusson AM et al. | β | 2006 | β |
| Comparison of nicotine pharmacokinetics in healthy Japanese male smokers following application of the transdermal nicotine patch and cigarette smoking. | Sobue S et al. | β | 2006 | β |
| Current status of immunologic approaches to treating tobacco dependence: vaccines and nicotine-specific antibodies. | LeSage MG et al. | β | 2006 | β |
| Cytochrome P450 pharmacogenetics and cancer. | Rodriguez-Antona C et al. | β | 2006 | β |
| Differential effects of passive immunization with nicotine-specific antibodies on the acute and chronic distribution of nicotine to brain in rats. | Pentel PR et al. | β | 2006 | β |
| Drugs and genotypes: how pharmacogenetic information could improve smoking cessation treatment. | Lee AM et al. | β | 2006 | β |
| Health practices and leukocyte DNA damage in Japanese hard-metal workers. | Lu Y et al. | β | 2006 | β |
| Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. | Malaiyandi V et al. | β | 2006 | β |
| Limitation of cigarette consumption by CYP2A6*4, *7 and *9 polymorphisms. | Minematsu N et al. | β | 2006 | β |
| The influence of genetics on nicotine dependence and the role of pharmacogenetics in treating the smoking habit. | Chatkin JM | β | 2006 | β |
| Cancer treatment and pharmacogenetics of cytochrome P450 enzymes. | van Schaik RH | β | 2005 | β |
| Function of human cytochrome P450s: characterization of the orphans. | Guengerich FP et al. | β | 2005 | β |
| Genetic influences on smoking: a brief review. | Al Koudsi N et al. | β | 2005 | β |
| Structures of human microsomal cytochrome P450 2A6 complexed with coumarin and methoxsalen. | Yano JK et al. | β | 2005 | β |